Bruno A Benitez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3688180/publications.pdf

Version: 2024-02-01

62 papers	7,823 citations	136950 32 h-index	155660 55 g-index
74 all docs	74 docs citations	74 times ranked	10855 citing authors

#	Article	IF	Citations
1	TREM2 Variants in Alzheimer's Disease. New England Journal of Medicine, 2013, 368, 117-127.	27.0	2,385
2	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 Td (edition	9.1	1,430
3	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimerâ€™s disease. Nature, 2014, 505, 550-554.	27.8	425
4	GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimerâ€™s Disease. Neuron, 2013, 78, 256-268.	8.1	344
5	Coding variants in TREM2 increase risk for Alzheimer's disease. Human Molecular Genetics, 2014, 23, 5838-5846.	2.9	263
6	TREM2Variant p.R47H as a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 449.	9.0	221
7	TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. Acta Neuropathologica, 2020, 140, 513-534.	7.7	186
8	Meningeal lymphatics affect microglia responses and anti-Aî² immunotherapy. Nature, 2021, 593, 255-260.	27.8	179
9	The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimerâ€™s disease risk. Science Translational Medicine, 2019, 11, .	12.4	170
10	A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimer's Research and Therapy, 2019, 11, 71.	6.2	131
11	TREM2 is associated with the risk of Alzheimer's disease in Spanish population. Neurobiology of Aging, 2013, 34, 1711.e15-1711.e17.	3.1	130
12	TREM2 is associated with increased risk for Alzheimerâ€™s disease in African Americans. Molecular Neurodegeneration, 2015, 10, 19.	10.8	130
13	Missense variant in TREML2 protects against Alzheimer's disease. Neurobiology of Aging, 2014, 35, 1510.e19-1510.e26.	3.1	110
14	Variants in GBA , SNCA , and MAPT influence Parkinson disease risk, age at onset, and progression. Neurobiology of Aging, 2016, 37, 209.e1-209.e7.	3.1	106
15	Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nature Neuroscience, 2021, 24, 1302-1312.	14.8	105
16	Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort. Alzheimer's Research and Therapy, 2012, 4, 34.	6.2	103
17	APOE genotype regulates pathology and disease progression in synucleinopathy. Science Translational Medicine, 2020, 12, .	12.4	102
18	Exome-Sequencing Confirms DNAJC5 Mutations as Cause of Adult Neuronal Ceroid-Lipofuscinosis. PLoS ONE, 2011, 6, e26741.	2.5	101

#	Article	IF	Citations
19	Regulation of ceramide-induced neuronal death: Cell metabolism meets neurodegeneration. Brain Research Reviews, 2009, 59, 333-346.	9.0	92
20	C9orf72 Hexanucleotide Repeat Expansions in Clinical Alzheimer Disease. JAMA Neurology, 2013, 70, 736.	9.0	92
21	TREM2 and neurodegenerative disease. New England Journal of Medicine, 2013, 369, 1567-8.	27.0	81
22	Resequencing analysis of five Mendelian genes andÂthe top genes from genome-wide association studies in Parkinsonâ€™s Disease. Molecular Neurodegeneration, 2016, 11, 29.	10.8	70
23	Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20097-20103.	7.1	68
24	TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. Molecular Neurodegeneration, 2019, 14, 18.	10.8	58
25	Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms. Neuron, 2021, 109, 2413-2426.e7.	8.1	57
26	The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE-Îµ4 Carriers. PLoS Genetics, 2013, 9, e1003685.	3.5	55
27	Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. BMC Neurology, 2017, 17, 198.	1.8	55
28	Analysis of functional polymorphisms in three synaptic plasticity-related genes (BDNF, COMT AND) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.9	52
29	The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathologica, 2020, 139, 45-61.	7.7	51
30	Parkinson disease is not associated with C9ORF72 repeat expansions. Neurobiology of Aging, 2013, 34, 1519.e1-1519.e2.	3.1	44
31	Frontobasal gray matter loss is associated with the TREM2 p.R47H variant. Neurobiology of Aging, 2014, 35, 2681-2690.	3.1	39
32	Exploration of genetic susceptibility factors for Parkinsonâ€™s disease in a South American sample. Journal of Genetics, 2010, 89, 229-232.	0.7	37
33	Macrophage secretion of miR-106b-5p causes renin-dependent hypertension. Nature Communications, 2020, 11, 4798.	12.8	36
34	Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?. Expert Opinion on Therapeutic Targets, 2018, 22, 587-598.	3.4	27
35	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	5.3	26
36	Neuronal VCP loss of function recapitulates FTLD-TDP pathology. Cell Reports, 2021, 36, 109399.	6.4	25

#	Article	IF	Citations
37	Functional reduction of SK3-mediated currents precedes AMPA-receptor-mediated excitotoxicity in dopaminergic neurons. Neuropharmacology, 2011, 60, 1176-1186.	4.1	23
38	Overlapping genetic architecture between Parkinson disease and melanoma. Acta Neuropathologica, 2020, 139, 347-364.	7.7	23
39	Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease. Frontiers in Neuroscience, 2018, 12, 230.	2.8	21
40	Primary fibroblasts from CSPÎ± mutation carriers recapitulate hallmarks of the adult onset neuronal ceroid lipofuscinosis. Scientific Reports, 2017, 7, 6332.	3.3	20
41	Genetic variation of the retromer subunits VPS26A/B-VPS29 in Parkinson's disease. Neurobiology of Aging, 2014, 35, 1958.e1-1958.e2.	3.1	19
42	Examination of the Effect of Rare Variants in TREM2, ABI3, and PLCG2 in LOAD Through Multiple Phenotypes. Journal of Alzheimer's Disease, 2020, 77, 1469-1482.	2.6	18
43	Clinically early-stage CSPÎ± mutation carrier exhibits remarkable terminal stage neuronal pathology with minimal evidence of synaptic loss. Acta Neuropathologica Communications, 2015, 3, 73.	5.2	17
44	Genetic high throughput screening in Retinitis Pigmentosa based on high resolution melting (HRM) analysis. Experimental Eye Research, 2013, 116, 386-394.	2.6	14
45	Exome sequencing revealed PDE11A as a novel candidate gene for early-onset Alzheimerâ€™s disease. Human Molecular Genetics, 2021, 30, 811-822.	2.9	12
46	TMEM230 in Parkinson's disease. Neurobiology of Aging, 2017, 56, 212.e1-212.e3.	3.1	9
47	Functional genomic analyses uncover APOE-mediated regulationÂofÂbrain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. Acta Neuropathologica Communications, 2020, 8, 196.	5.2	8
48	Cell-autonomous expression of the acid hydrolase galactocerebrosidase. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9032-9041.	7.1	8
49	Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease. Neurology, 2022, 99, .	1.1	8
50	Pooled-DNA target sequencing of Parkinson genes reveals novel phenotypic associations in Spanish population. Neurobiology of Aging, 2018, 70, 325.e1-325.e5.	3.1	6
51	Pooled-DNA Sequencing for Elucidating New Genomic Risk Factors, Rare Variants Underlying Alzheimerâ€™s Disease. Methods in Molecular Biology, 2016, 1303, 299-314.	0.9	3
52	Quantitative endophenotypes as an alternative approach to understanding genetic risk in neurodegenerative diseases. Neurobiology of Disease, 2021, 151, 105247.	4.4	3
53	Study of genetic variants in the BDNF, COMT, DAT1 and SERT genes in Colombian children with attention deficit disorder. Revista Colombiana De PsiquiatrÃa (English Ed), 2017, 46, 222-228.	0.3	1
54	Functional exploration of AGFG2, a novel player in the pathology of Alzheimer disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e054240.	0.8	1

#	Article	IF	Citations
55	P4-117 A study of polymorphisms in APOE, ACE, A2M and TAU genes and their relation with lipid and apolipoprotein E serum concentrations in Colombian patients with Alzheimer's disease. Neurobiology of Aging, 2004, 25, S508.	3.1	0
56	O1-04-02: EXOME-SEQUENCING IN LATE-ONSET FAMILIES IDENTIFIED ADDITIONAL CANDIDATES GENES FOR ALZHEIMER'S DISEASE. , 2014, 10, P135-P135.		0
57	O1-04-05: NOVEL CODING VARIANTS IN TREM2 INCREASE RISK FOR ALZHEIMER'S DISEASE. , 2014, 10, P136-P136.		0
58	Proteogenomic analysis of cerebrospinal fluid reveals causal role of proteins from the autophagyâ€lysosome pathway in Parkinsonâ€™s disease. Alzheimer's and Dementia, 2020, 16, e043422.	0.8	0
59	DNAJC5 affects the endoâ€lysosomal pathway, APP processing, and AD pathology in vitro and in vivo. Alzheimer's and Dementia, 2021, 17, e054177.	0.8	0
60	Profiling the metabolic landscape of AD. Alzheimer's and Dementia, 2021, 17, e050086.	0.8	0
61	Single nuclei RNA-sequencing of GWAS loci variant carriers elucidates cell-types and transcriptional profile alterations associated with Alzheimer disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e054402.	0.8	0
62	Multi-omics approaches reveal a link between the MS4A gene loci, TREM2, and microglia function.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e054553.	0.8	0